Lcnb Corp lifted its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 64.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,268 shares of the biopharmaceutical company’s stock after acquiring an additional 2,843 shares during the quarter. Lcnb Corp’s holdings in Bristol-Myers Squibb were worth $402,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in BMY. DnB Asset Management AS grew its stake in Bristol-Myers Squibb by 0.3% in the second quarter. DnB Asset Management AS now owns 321,762 shares of the biopharmaceutical company’s stock valued at $17,806,000 after acquiring an additional 900 shares during the period. Mcmillion Capital Management Inc. grew its stake in Bristol-Myers Squibb by 1.4% in the second quarter. Mcmillion Capital Management Inc. now owns 64,044 shares of the biopharmaceutical company’s stock valued at $3,544,000 after acquiring an additional 903 shares during the period. Securian Asset Management Inc grew its stake in Bristol-Myers Squibb by 0.5% in the second quarter. Securian Asset Management Inc now owns 167,108 shares of the biopharmaceutical company’s stock valued at $9,248,000 after acquiring an additional 912 shares during the period. Itau Unibanco Holding S.A. grew its stake in Bristol-Myers Squibb by 4.9% in the second quarter. Itau Unibanco Holding S.A. now owns 19,840 shares of the biopharmaceutical company’s stock valued at $1,096,000 after acquiring an additional 926 shares during the period. Finally, Gillespie Robinson & Grimm Inc. grew its stake in Bristol-Myers Squibb by 12.3% in the second quarter. Gillespie Robinson & Grimm Inc. now owns 8,679 shares of the biopharmaceutical company’s stock valued at $480,000 after acquiring an additional 950 shares during the period. Institutional investors own 72.29% of the company’s stock.

A number of research analysts have issued reports on the company. Atlantic Securities raised Bristol-Myers Squibb from an “underweight” rating to a “neutral” rating and set a $57.00 target price for the company in a research note on Wednesday, August 8th. SunTrust Banks reissued a “buy” rating and issued a $67.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, July 31st. Credit Suisse Group boosted their target price on Bristol-Myers Squibb from $58.00 to $61.00 and gave the company a “neutral” rating in a research note on Friday, July 27th. BMO Capital Markets boosted their target price on Bristol-Myers Squibb from $47.00 to $51.00 and gave the company a “market perform” rating in a research note on Monday, July 23rd. Finally, Jefferies Financial Group set a $58.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Sunday, July 15th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and six have assigned a buy rating to the company. Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $63.01.

Shares of Bristol-Myers Squibb stock opened at $61.31 on Monday. The stock has a market capitalization of $100.21 billion, a PE ratio of 20.37, a PEG ratio of 1.55 and a beta of 1.02. Bristol-Myers Squibb Co has a one year low of $49.96 and a one year high of $70.05. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.28 and a current ratio of 1.40.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $0.14. The company had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.48 billion. Bristol-Myers Squibb had a return on equity of 42.58% and a net margin of 1.74%. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.74 earnings per share. analysts predict that Bristol-Myers Squibb Co will post 3.62 earnings per share for the current fiscal year.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Featured Article: Average Daily Trade Volume – ADTV

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.